WHO可靠血清產品，無交叉凝集，質量保證，反應快速，為*優質血清產品。本司還提供德國SiFin優質血清，性價比高，為各高校實驗室，研究所推薦血清產品！丹麥SSI大腸桿菌血清型鑒定，廣州健侖生物公司提供產品及服務！變形桿菌診斷血清 OX2型 2ml

變形桿菌診斷血清 OX2型 2ml

廣州健侖生物科技有限公司

我司長期供應尼古丁（可替寧）檢測試劑盒，違禁品檢測試劑盒，單卡檢測，3聯卡到12聯卡，可以自由組合，根據您的需求自由組合，*，性價比高，產品質量很好。

保存要求：除了有特殊說明，免疫檢測產品應保存在2-8°C

產品規格：2ml/瓶

保質期：2年

本試劑盒主要用于對病菌細菌進行檢測，利用快速玻片凝集檢測技術

利用快速玻片凝集和對流免疫電泳(CIE)鑒定流感嗜血桿菌

變形桿菌OX2診斷血清-陽性對照品

變形桿菌OX2診斷血清-陽性對照品

單價血清變形桿菌診斷血清 OX2

單價血清變形桿菌診斷血清 OX2

單價血清變形桿菌診斷血清 OX19

單價血清變形桿菌診斷血清 OX19

單價血清變形桿菌診斷血清 OXK

單價血清變形桿菌診斷血清 OXK

2ml單價變形桿菌檢測血清 OX2

2ml單價變形桿菌檢測血清 OX2

2ml單價變形桿菌檢測血清 OX19

2ml單價變形桿菌檢測血清 OX19

2ml單價變形桿菌檢測血清 OXK

2ml單價變形桿菌檢測血清 OXK

變形桿菌診斷血清（單價O多價OMA)

變形桿菌診斷血清（單價O多價OMA)

變形桿菌診斷血清 OX2型 2ml

我司還有很多種血清學診斷血清、血液檢測、免疫檢測產品、毒素檢測、凝集檢測、酶免檢測、層析檢測、免疫熒光檢測產品，。

（ MOB：楊永漢）

我司還提供其它進口或國產試劑盒：登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團菌、化妝品檢測、食品安全檢測等試劑盒以及日本生研細菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產品。

想了解更多的產品及服務請掃描下方二維碼：

【公司名稱】 廣州健侖生物科技有限公司
【市場部】    楊永漢

【】 
【騰訊  】 
【公司地址】 廣州清華科技園創新基地番禺石樓鎮創啟路63號二期2幢101-103

 

盡管微生物的分離鑒定仍作為病原學檢測的金標準，但這種“以活菌生長”為基礎的傳統的細菌學鑒定方法速度較慢，不能適應臨床的需要，要求以標本的直接檢查為基礎，如形態、染色、抗原檢測及核酸檢測（核酸雜交、CR 和S rRNA 分析），檢測致病基因（致病島、毒力島）和耐藥基因。盡可能在快速診斷方面下工夫。．及時報告：要使實驗室數據有效地轉化為臨床有用的信息，病原微生物診斷報告應實行三段報告制度，即在涂片或培養陽性結果出現時、敏感試驗結果出來時以及zui終結果出來后都要及時報告。．加強質量控制，增加檢驗項目：臨床微生物室必須加強質量控制，保證各種標本的檢驗質量，為臨床提供可靠依據，并滿足臨床需要的各種檢驗項目。當前臨床微生物室應根據本單位的實際情況增加檢驗項目，臨床要求關注的一些項目有：）呼吸道標本的細菌學篩選和半定量培養方法；）呼吸道非典型病原體的檢測，包括衣原體、支原體和軍團菌；）非結核分枝桿菌的培養與藥敏；）免疫抑制或患者特殊病原體的檢測，如巨細胞病毒，卡氏肺孢子菌等；）抗生素相關腹瀉的病原體（主要是艱難梭菌）的檢測；）侵襲性真菌的快速檢測和藥敏試驗等。參與臨床會診（一）獲取臨床信息，做出及時、準確的微生物報告臨床感染性疾病往往涉及多種病原體，沒有任何一個單一的試驗能夠檢出所有潛在病原體。因此，臨床信息是選擇試驗方法的重要參考依據。
Although the isolation and identification of microorganisms is still the gold standard for etiological detection, the traditional method of bacteriological identification based on "live bacteria growth" is slow and cannot adapt to clinical needs. It requires the direct examination of specimens as the basis. , such as morphology, staining, antigen detection and nucleic acid detection (nucleic acid hybridization, CR and S rRNA analysis), detection of pathogenic genes (pathogenic islands, Virulence Island) and drug resistance genes. As much as possible in the rapid diagnosis. . Timely reporting: To effectively convert laboratory data to clinically useful information, the diagnostic report for pathogenic microorganisms should implement a three-stage reporting system, that is, when a positive smear or culture result occurs, when a sensitive test result comes out, and when the final result comes out. Report it in a timely manner. . Strengthen quality control and increase inspection items: The clinical microbiology room must strengthen quality control, ensure the quality of various specimens, provide a reliable basis for clinical practice, and meet various clinical testing needs. The current clinical microbiology laboratory should increase the testing items according to the actual conditions of the unit. Some of the clinical requirements are: bacteriological screening and semi-quantitative culture methods for respiratory specimens; detection of atypical pathogens of the respiratory tract, including chlamydia, mycoplasma, and corps Bacteria;) Culture and drug susceptibility of non-tuberculous mycobacteria;) Immunosuppression or detection of patient-specific pathogens, such as cytomegalovirus, Pneumocystis carinii, etc.;) Pathogens of antibiotic-associated diarrhea (mainly Clostridium difficile) Detection;) Rapid detection of invasive fungi and drug susceptibility testing. Participate in clinical consultations (a) Obtain clinical information and make timely and accurate reports on microbiology Clinical infectious diseases often involve multiple pathogens. No single test can detect all potential pathogens. Therefore, clinical information is an important reference for selecting test methods. Clinicians should state the patient's speculative diagnosis when opening a laboratory test, so that the experimenter can select reasonable test procedures and test methods accordingly, and can guide clinically correct collection of appropriate specimens; when the laboratory begins to have experimental results The clinician must be notified in time for them to re-evaluate the treatment plan.